Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

76.000
+2.2503.05%
Volume:2.57M
Turnover:192.12M
Market Cap:42.83B
PE:50.42
High:76.200
Open:73.800
Low:72.600
Close:73.750
52wk High:126.600
52wk Low:63.300
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:1.30
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.507
ROE:109.10%
ROA:39.01%
PB:4.41
PE(LYR):50.42
PS:4.58

Loading ...

HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%

Tiger Newspress
·
Jun 05

RemeGen Records Stable Share Base in April 2026; Public Float Fully Compliant

Bulletin Express
·
Jun 04

RemeGen Maintains Stable Share Capital in May 2026, Public Float Fully Compliant

Bulletin Express
·
Jun 04

Stock Track | REMEGEN Plummets 5.22% Intraday as US-China Regulatory Barriers Escalate for Biotech Sector

Stock Track
·
Jun 03

Movement Alert|RemeGen Falls 5.02% in Regular Trading, US-China Biotech Regulatory Barriers Escalation Pressures Innovative Drug Outbound Valuation

Market Focus
·
Jun 03

Stock Track | RemeGen Plummets 5.42% Intraday Amid US-China Biotech Regulatory Pressures

Stock Track
·
Jun 02

Movement Alert|RemeGen Intraday Decline 5.48% in Regular Trading, US-China Biotech Regulatory Escalation Continues to Pressure Innovative Pharma Sector

Market Focus
·
Jun 02

RemeGen invests RMB300.00 million in SPDB structured deposit, raising total cash-management exposure to RMB1.00 billion within two months

Bulletin Express
·
Jun 01

REMEGEN to Deploy 300 Million Yuan of Idle Capital in Wealth Management Product from SPDB

Stock News
·
Jun 01

Stock Track | RemeGen Plummets 5.38% Intraday Amid Escalating US-China Biotech Regulatory Tensions

Stock Track
·
Jun 01

Movement Alert|RemeGen Falls 5.08% in Regular Trading, US-China Biotech Regulatory Escalation Pressures Innovative Drug Sector

Market Focus
·
Jun 01

Movement Alert|RemeGen Rises 5.13% in Regular Trading, FDA Greenlights Telitacicept Phase II Trial for IgA Nephropathy in the US

Market Focus
·
May 29

Orient Securities Reduces Stake in REMEGEN, Selling 160,000 Shares at Average Price of HK$84.83

Stock News
·
May 26

REMEGEN Allocates Additional RMB 60 Million to Huatai Securities Wealth Management Product

Stock News
·
May 26

Huitianfu Fund Trims Stake in REMEGEN by 160,000 Shares at Approximately HK$84.83 Each

Deep News
·
May 24

Huatai-PineBridge Fund Reduces Stake in REMEGEN by 160,000 Shares at Average Price of HK$84.83

Stock News
·
May 22

Junshi Biosciences Gets Nod for New Indication for Toripalimab; Shares Down 4%

MT Newswires Live
·
May 22

Movement Alert|RemeGen Rises 3.55% in Regular Trading, Biotech Sector Rally and Strong Q1 Earnings Drive Rebound

Market Focus
·
May 21

RemeGen Allocates Additional RMB50.00 Million to HTSC Wealth Management Products, Raising Total Deployment to RMB538.00 Million

Bulletin Express
·
May 20

RemeGen Plans Board Transition, 20% Share Issuance Mandate, and Redirects IPO Proceeds Amid 2025 Profit Turnaround

Bulletin Express
·
May 20